BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29074183)

  • 1. Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples.
    Ejegod DM; Junge J; Franzmann M; Kirschner B; Bottari F; Sideri M; Sandri MT; Bonde J
    Papillomavirus Res; 2016 Dec; 2():31-37. PubMed ID: 29074183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions.
    Bottari F; Sideri M; Gulmini C; Igidbashian S; Tricca A; Casadio C; Carinelli S; Boveri S; Ejegod D; Bonde J; Sandri MT
    J Clin Microbiol; 2015 Jul; 53(7):2109-14. PubMed ID: 25903574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
    Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens.
    Wright TC; Stoler MH; Agreda PM; Beitman GH; Gutierrez EC; Harris JM; Koch KR; Kuebler M; LaViers WD; Legendre BL; Leitch SV; Maus CE; McMillian RA; Nussbaumer WA; Palmer ML; Porter MJ; Richart GA; Schwab RJ; Vaughan LM
    Am J Clin Pathol; 2014 Jul; 142(1):43-50. PubMed ID: 24926084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
    Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
    Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
    Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
    Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study.
    Ejegod DM; Rebolj M; Bonde J
    BMC Cancer; 2015 Apr; 15():216. PubMed ID: 25886410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
    Clad A; Reuschenbach M; Weinschenk J; Grote R; Rahmsdorf J; Freudenberg N
    J Clin Microbiol; 2011 Mar; 49(3):1071-6. PubMed ID: 21191046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper C
    Am J Clin Pathol; 2019 Mar; 151(4):433-442. PubMed ID: 30649177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of BD Onclarity HPV assay on FLOQSwabs vaginal self-samples.
    Martinelli M; Latsuzbaia A; Bonde J; Pedersen H; Iacobone AD; Bottari F; Piana AF; Pietri R; Cocuzza CE; Arbyn M;
    Microbiol Spectr; 2024 Mar; 12(3):e0287223. PubMed ID: 38323823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
    Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
    PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical and clinical performance of extended HPV genotyping with BD Onclarity HPV Assay in home-collected first-void urine: A diagnostic test accuracy study.
    Van Keer S; Latsuzbaia A; Vanden Broeck D; De Sutter P; Donders G; Doyen J; Tjalma WAA; Weyers S; Arbyn M; Vorsters A
    J Clin Virol; 2022 Oct; 155():105271. PubMed ID: 36049283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of a human papillomavirus E6 and E7 oncoprotein test for the diagnosis of cervical precancer and cancer.
    Zhang JJ; Cao XC; Zheng XY; Wang HY; Li YW
    J Int Med Res; 2018 Mar; 46(3):1033-1042. PubMed ID: 29322839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
    Fokom Domgue J; Schiffman M; Wentzensen NH; Gage JC; Castle PE; Raine-Bennett TR; Fetterman B; Lorey T; Poitras NE; Befano B; Xie Y; Miachon LS; Dean M
    J Clin Microbiol; 2017 Aug; 55(8):2348-2355. PubMed ID: 28515214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical performance of RNA isolated from BD SurePath™ cervical cytology specimens by the PreTect™ HPV-Proofer assay.
    Dixon EP; Grønn P; King LM; Passineau H; Doobay H; Skomedal H; Hariri J; Hay SN; Brown CA; Fischer TJ; Malinowski DP
    J Virol Methods; 2012 Nov; 185(2):199-203. PubMed ID: 22820075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
    Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
    J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.
    Cuschieri K; Geraets DT; Moore C; Quint W; Duvall E; Arbyn M
    J Clin Microbiol; 2015 Oct; 53(10):3272-9. PubMed ID: 26246482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of p16/Ki67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS.
    Zhu Y; Ren C; Yang L; Zhang X; Liu L; Wang Z
    BMC Cancer; 2019 Mar; 19(1):271. PubMed ID: 30917784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix.
    Lapierre SG; Sauthier P; Mayrand MH; Dufresne S; Petignat P; Provencher D; Drouin P; Gauthier P; Dupuis MJ; Michon B; Ouellet S; Hadjeres R; Ferenczy A; Franco EL; Coutlée F
    J Clin Microbiol; 2012 Apr; 50(4):1240-4. PubMed ID: 22301023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.